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sources. Direct costs of diabetes complications and drug treat-
ment were projected over patients’ lifetimes from a UK National
Health Service perspective. Both costs and QALYs were dis-
counted at 3.5% p.a. Sensitivity analyses were performed.
RESULTS: The model projected that treatment with IAsp would
result in an additional 0.08 LYG and 0.09 QALYs per patient.
Total lifetime costs/patient were estimated to increase by £419.
The cost/LYG was calculated to be £5430 and cost/QALY
£4825. CONCLUSION: The model predicted that treatment
with insulin aspart would result in long-term improvements in
health outcomes and quality of life compared to soluble human
insulin in patients with type-1 diabetes. The cost-effectiveness
result is well within the range considered to represent good value
for money in the UK.
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OBJECTIVE: In their evaluation of the cost effectiveness of
insulin glargine, NICE included an assumption that switching to
insulin would result in decreased health utility (8%). This altered
notably any resulting cost-utility ratios. The purpose of this
study was to test this hypothesis. METHODS: The design was
a before-and-after study for type-2 patients who required switch-
ing to insulin. All followed an algorithm to achieve fasting and
post-prandial blood glucose targets. Outcome measures included
a measure of utilit (EQ5Dindex) at baseline, three-months and six-
months. This report was a preliminary analysis of the ﬁrst 48
subjects, of which 32 had completed 12 weeks and 26 had com-
pleted the full 24-week study. RESULTS: Of the 26 subjects, 21
(81%) remained on glargine with or without OHAs, two
required additional pre-meal boluses, and three required twice-
daily pre-mixtures. The mean (SD) EQ5Dindex at baseline was
0.655 (0.275; n = 24), at three-months 0.637 (0.333; D vs. base-
line NS) and at six-months 0.710 (0.319; D vs. baseline NS). At
three-months, six patients had worse utility and six better utility,
while 12 reported no change. At six-months, four patients had
worse utility after switching, and 11 had better utility, the
remaining nine subjects reported no change. Over the six-
months, mean BMI increased from 29.4 to 30.0kg/m2 (n = 23,
p < 0.001) and mean HbA1c decreased from 10.1% to 7.8% (n
= 23, p < 0.001). Mean daily insulin dose at six-months was 61.6
units (range 24 to 178). CONCLUSIONS: This is a limited but
important interim analysis. The hypothesis that switching to
insulin–here insulin glargine—resulted in a notable decrease in
utility (quality of life) was rejected, with a trend for a clinically
meaningful improvement in utility. Economic evaluations
should, therefore, exclude this assumption. This observation is
not necessarily generalisable to all insulin regimens.
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OBJECTIVES: To evaluate the impact of cardiovascular co-
morbidity on total and diabetes-related health care costs in
patients with type-2 diabetes. METHODS: Retrospective analy-
sis of a state Medicaid claims data was conducted in patients
with type-2 diabetes identiﬁed using ICD-9 diagnosis codes
(250.0¥–250.9¥, where x = 0 or two) in the year 2001. Patients
≥65 years or those with managed care coverage were excluded.
Presence of cardiovascular co-morbidity in the year 2001 was
identiﬁed using appropriate ICD-9 codes. Semi-logarithmic OLS
models were used to estimate the impact of cardiovascular co-
morbidity on total and diabetes-related health care costs in year
2002, controlling for demographic characteristics (age, gender,
race, and urban/rural location), presence of peripheral vascular
conditions, cerebrovascular conditions, hypertension, hyperlipi-
demia, and other co-morbid conditions. Two-part models were
used for estimating the impact of cardiovascular co-morbidity on
speciﬁc costs such as ER/hospitalization, outpatient and pre-
scription. Smearing estimates were used to interpret the results
from the semi-logarithmic models. RESULTS: Presence of car-
diovascular co-morbidity had a signiﬁcant impact on all cate-
gories of total and diabetes-related health care costs, except
diabetes-related prescription drug costs. Type-2 diabetes patients
with cardiovascular co-morbidity had signiﬁcantly higher 
total health care costs (38.9%, $12,550 vs. $9,031), ER/
hospitalization costs (239.8%, $4,845 vs. $1,426), outpatient
costs (35.3%, $3,956 vs. $2,925) and prescription drug costs
(15.1%, $4,686 vs. $4,071) compared to those without cardio-
vascular co-morbidity. Similarly, type-2 diabetes patients with
cardiovascular co-morbidity had signiﬁcantly higher diabetes-
related total health care costs (59.7%, $4349 vs. $2724),
ER/hospitalization costs (346.8%, $1911 vs. $428) and outpa-
tient costs (17.4%, $740 vs. $631) compared to patients without
cardiovascular co-morbidity. CONCLUSIONS: Presence of car-
diovascular co-morbidity in patients with type-2 diabetes signif-
icantly increases total and diabetes-related health care costs, with
ER/hospitalization costs accounting for the highest percentage
increase.
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OBJECTIVE: To examine the impact of pre-existing depression
on utilization patterns and adherence to oral hypoglycemic
agents (OHAs) in patients newly diagnosed with type-2 diabetes.
METHODS: Newly diagnosed type-2 diabetes patients during
the three-year period (1998–2000) were identiﬁed from a Med-
icaid claims database. Presence of pre-existing depression was
determined on the basis of ICD-9 CM codes for depression. 
Utilization patterns (switching, augmentation) and adherence to
OHAs were computed for a 12-month follow up period from the
date of the index OHA prescription. A multivariate framework
was used to estimate the impact of depression on utilization pat-
terns and adherence, controlling for confounders such as demo-
graphics, co-morbidity, diabetes severity, regimen complexity,
and interaction with health care providers. RESULTS: A total of
1326 newly diagnosed type-2 diabetes patients were identiﬁed
(depressed = 471; non-depressed = 855). A signiﬁcantly higher
number of depressed patients (23.3%) switched or augmented
therapy as compared to non-depressed patients (16.2%). Results
of a multinomial logit model indicated that controlling for
covariates, patients with depression were 1.7 times more likely
to switch (p = 0.046) and two times more likely to augment
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therapy (p = 0.003) as compared to non-depressed patients.
Results of an extended-Cox proportional hazard model indicated
that the hazard to switch/augment therapy was 2.4 times more
for depressed patients as compared to non-depressed patients 
in the latter six-months of the follow-up period (p = 0.0005).
Depression was consistently found to be a signiﬁcant predictor
of adherence, with depressed patients being 3–6% less adherent
to their OHAs than non-depressed patients. CONCLUSION:
Depression signiﬁcantly impacts utilization patterns and adher-
ence to OHAs in patients with type-2 diabetes. This lack of
adherence may affect glycemic control and consequently inci-
dence of diabetes related complications. The study results imply
that depression screening and treatment may be included in the
protocol for management of type-2 diabetes patients.
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OBJECTIVE: Measure the effect of non-adherence to oral antidi-
abetic medications on total and diabetes-attributable health care
costs in a managed care population. METHODS: Using a large
managed care administrative claims database, all patients with a
prescription for an oral antidiabetic from January, 2000 through
June, 2001 were selected (n = 54,505) from among continuously
eligible patients age 18 years and older. Total and diabetes-
attributable costs were computed during one year of follow-up.
A non-adherence variable, the total number of days that each
patient was without antidiabetic medication, was computed. The
computation allowed for stashing of antidiabetics within classes
but not across classes (alpha-glucosidase, metformin, other 
secretagogues, sulfonylureas, thiazolidinediones). Multivariate
log-linear regressions were estimated for costs using adherence,
diabetes severity, overall comorbidity burden, hospitalization in
prior six-months, concomitant insulin use, patient initiating
antidiabetic therapy, insurance plan, and demographic variables.
RESULTS: Overall, total and diabetes-attributable costs
decreased with worsened adherence to oral antidiabetics.
However, for the most costly patients (top 40%, median annual
costs of $9391), there was a 1.66% increase in total costs for
each 30 additional days without oral medication. Only patients
with the top 10% of attributable costs had increased diabetes-
attributable costs with worsening adherence. After excluding the
cost of prescription antidiabetic medications, non-adherence
increased costs in all but the lowest-cost patients (bottom 30%).
The top 40%, with median non-drug attributable costs of $1339,
realized a 6.38% cost increase with each 30 days without med-
ication and the middle 30%, with median of $741, realized a
3.76% increase. CONCLUSIONS: During one year of follow-
up, non-adherence to oral antidiabetics increased total and dia-
betes-attributable costs for the most resource-intensive patients
but did not increase average costs for the population overall. For
the 70% of patients with the highest diabetes-attributable costs,
worsening adherence increased the medical services portion of
diabetes-attributable costs.
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OBJECTIVES: This study aims to evaluate medication adher-
ence, utilization and costs associated with American Pharmacist
Association’s (AphA) Diabetes Care Project. METHODS:
Patients with diabetes were assigned to an intervention or control
cohort based on enrollment in APhA’s Diabetes Care Project.
Individual patients were included if they had at least two claims
for diabetes medications and were continuously enrolled from
April 1, 2002 to March 31, 2004. Retrospective pre-post cohort
design, descriptive and multivariate modeling analyses were 
conducted to compare medication utilization between the two
cohorts. RESULTS: A total of 118 patients (37 in the interven-
tion and 81 in the comparison) were identiﬁed. There were no
signiﬁcant differences between the two cohorts in medication
possession ratio (MPR), pharmacy costs, and the number of 
prescriptions of diabetes drugs, ACE inhibitors, and needles at
baseline. During the 12-month post period, patients in the inter-
vention were more likely to have a prescription for test strips
(OR = 144.9, p < 0.0001) and needles (OR = 11.7, p < 0.0001).
Compared to the baseline period, patients with pharmacist inter-
vention had signiﬁcantly more prescriptions for test strips (0.68
vs. 5.32), diabetes medications (6.24 vs. 11.41), needles (1.27 vs.
4.24) and ACE inhibitors (1.68 vs. 3.03), a higher MPR with
diabetes drugs (0.67 vs. 0.96) and higher pharmacy costs ($689.9
vs. $1617.8), whereas patients in the comparison had no signif-
icant differences. CONCLUSIONS: APhA Diabetes Care Project
signiﬁcantly increased patients?adherence to therapy and uti-
lization for test strips, needles, diabetes medications and ACE
inhibitors. The increased adherence to therapy may offer both
clinical and cost beneﬁts to patients. (Acknowledgments: 
American Pharmacists Association; The Manitowoc Health Care
Coalition; Don F. Jabas Associates.)
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OBJECTIVE: To investigate the effects of a disease manage-
ment program on diabetic adults in a Medicaid population.
METHODS: This study was a retrospective database analysis of
diabetes-related costs and utilization and of overall costs. A pre-
post design with a concurrent control group was employed. To
ensure appropriate comparability, the study group and control
group were matched using propensity scoring techniques. Data
available for analysis spanned from July, 2000 to May, 2004,
while rolling enrollment period for the disease management
program occurred between October, 2002 and July, 2003.
RESULTS: From a potential pool of 2921 diabetics that were
identiﬁed within a Medicaid program, a study population of 388
was initially assessed for eligibility within counties that were 
targeted to implement the disease management program. After
applying exclusion criteria, 122 diabetics began enrollment
within the program. Ultimately, 32 diabetics completed the 12
month disease management program. Results indicated that
mean monthly diabetes-related medical costs per patient were
$190 in the pre-period and $225 in the post-period. Mean
monthly total medical costs per patient were $930 in the pre-
period and $939 in the post-period. Mean monthly pharmacy
costs per patient were $378 in the pre-period and $473 in the
post-period. Further multivariate analysis adjusted for demo-
graphic characteristics, initial utilization, and chronic disease
score. CONCLUSIONS: Higher costs in the post-period may be
associated with increased levels of care motivated by participa-
tion in the program. For a disease such as diabetes, the positive
long-term effects due to better care may not be apparent in the
short period of time during which the study data was gathered.
A longer-term analysis is warranted. In addition, a small pro-
portion of patients (8.2%) completed the full 12-month diabetes
